Hepatitis C virus (HCV) is estimated to chronically infect 180 million people worldwide.
According to WHO, 15 to 30% of these chronically infected persons will develop cirrhosis and hepatocellular carcinoma (HCC). Approximately 700 000 persons die each year from HCV-related liver diseases.
The recent advances in research have made the development of new efficient direct acting antivirals (DAAs) possible that revolutionized the field of hepatitis C treatment with sustained virological responses higher than 90% for all genotypes and subgroups of patients. Despite the high efficacy of these new DAAs, HCV remains a real global burden and the search for an efficient vaccine is still ongoing.
The new EASL Recommendations on Treatment of Hepatitis C 2016 were released on 22 September and live streamed from Paris. At the same time, EASL also organised a special conference on HCV in Paris, where leading experts provided the latest updates in the field as well as critical reviews and analysis on the best way to achieve HCV elimination.